Dassault Systèmes in talks to buy drug trial software company for about $2bn

Dassault Systèmes is reportedly in discussions to acquire ArisGlobal, a leading drug trial software company, for approximately $2 billion. This potential deal would significantly enhance the French conglomerate's foothold in the life sciences sector. By integrating ArisGlobal's advanced software solutions, Dassault Systèmes aims to bolster its capabilities in designing and managing clinical trials, which is crucial given the growing importance of digital tools in the pharmaceutical industry. This acquisition underscores Dassault Systèmes' strategic focus on expanding its influence in high-growth areas like life sciences.